An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Clinical trial NCT04717414 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04717414
Sponsor: Celgene
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Myeloproliferative Disorders Myelofibrosis Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis Anemia

Start date: 2021-02-25
Primary completion: 2025-05-26
Enrollment: 313

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.